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Salmon and human calcitonin like material in lung cancer
C. Gropp, W. Luster & K. Havemann
Department ofHematology/Oncology - University ofMarburg, FRG.
Human calcitonin (hCT) like material has been
detected in plasma, urine and tissue extracts of
patients with medullary thyroid carcinoma (MTC)
and lung cancer as well as in the incubation
medium of cultured cells of these tumours
(Bertagna et al., 1978; Ellison et al., 1975;
Goltzman & Tischler, 1978; Goltzman et al., 1974;
Gropp et al., 1980a,b; Ham et al., 1980; Luster et
al., 1982; Milhaud et al., 1974; Silva et al., 1974;
Sizemore & Heath, 1975). The hCT immunoreactive
material has been shown to be useful as tumour
markers in patients with MTC and with small cell
lung cancer (SCLC) to determine prognosis and
response to therapy (Goltzman et al., 1974; Gropp
et al., 1980a,b). The hCT has not only been
detected in man but also in protochordates (Galan
et al., 1981a, Girgis et al., 1980), in amphibia
(Galan Galan et al., 1981b, Perez Cano et al., 1981)
and in birds (Perez Cano et al., 1982). In these
animals hCT coexists with other calcitonins like
salmon calcitonin (sCT). Recently the existence of
sCT in human thyroid and brain has been described
by Fischer et al., 1983. This study shows for the
first time the coexistence of both hCT- and sCT-
like material in sera of patients with SCLC and in
the culture medium of established lung cancer cell
lines.
hCT and sCT were determined simultaneously in
about 100 patients with histologically proven SCLC
before therapy. Prior to therapy, extent of disease
was determined by physical examination, liver
function tests, chest and bone X-rays, broncho-
and/or mediastinoscopy, bone marrow examination,
ultrasound, computerized tomography and nuclear
scans of the bone. Patients were divided into
limited and extensive categories. Limited disease
implied that the disease was confined to one
hemithorax with or without mediastinal node
disease, with or without ipsilateral supraclavicular
node involvement and with or without ipsilateral
small pleural effusion (without malignant cells).
Extensive disease was defined as disease beyond the
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confines of the definition of limited disease. Both
calcitonins were also assayed in the medium of lung
tumour cell lines established in our laboratory
(Gropp et al., 1984, Luster et al., 1984). For
comparison, the culture medium of our medullary
carcinoma cell lines were also studied as well as 18
sera of patients with medullary carcinoma of the
thyroid. Permanent cell cultures were established
from small cell, large cell, squamous and adeno
carcinoma of the lung. All purification steps leading
to a permanent cell line were controlled by cyto-
logical analysis. Cell lines of small cell carcinoma
were derived from pleural or pericardial exudates.
Specimens were collected with an anticoagulant,
centrifuged and then separated from erythrocytes
and cell debris by ficoll gradient (Pharmacia
Uppsala, Sweden) centrifugation 30min at 800g.
The fraction containing the tumour cells was
carefully collected and washed in a 10-fold volume
of MEM Dulbecco's or RPMI-1640 cell culture
medium (Boehringer Mannheim, FRG). The cells
were resuspended in the same medium containing
16.6% of foetal calf serum (Paesel Frankfurt,
FRG), diluted to 105 cells ml-I and plated into cell
culture flasks (Nunc Roskilde, Denmark). Non
small cell lung tumour cell lines were established
from surgically obtained fresh tumour tissue. Solid
tissue specimens were washed with antibiotics (0.5g
streptomycin, 50,000i.u. penicillin and 250og
amphotericin B ml-1 PBS) and minced into 1-
3 mm3 pieces. To obtain a cell suspension the
material was disintegrated by collagenase
(0.5mgml-1 PBS, Boehringer Mannheim, FRG) 3
times for 15min at 20°C. In the case of an
incomplete disintegration after this procedure an
incubation in the presence of 0.5mgml- I
collagenase and 0.5% trypsin (Boehringer
Mannheim, FRG) was followed. Washing and
culture of the tumour cells was performed as
described above for the small cell tissue cultures.
After growth of the cells to confluency or to 1 to
5 x 10' cells per culture flask the medium was
analyzed for peptide hormone content. The positive
cell cultures were cloned in microplates, analyzed
for peptide hormones and recloned. If necessary
such clones were submitted to an additional
purification by soft agar cloning.
( The Macmillan Press Ltd., 1985898 C. GROPP et al.
hCT was determined by means of a commercial
radioimmunoassay using an antiserum against syn-
thetichCT(1-32)asdescribed previously (Lusteretal.,
1982). sCT was determined by a radioimmunoassay
using an antiserum against sCT (16-32) which
showed no cross reactivity against hCT. The double
antibody radioimmunoassay was obtained from
Diagnostik System Laboratories (Webster, Texas)
and is not available commercially.
For further characterization of the hCT- and
sCT-like material the incubation medium of two
small cell lung cancer cell lines was subjected to gel
chromatography and the fractions were assayed
simultaneously for hCT and sCT. For this study
3ml samples of culture medium were subjected to
gel filtration on a 1.5 x 90cm column of ACA 54
(LKB Stockholm, Sweden), equilibrated with
80mMKH2PO4, 0.4M EDTA and 0.1% NaN3,
pH 7.4, or with the same buffer containing
proteinase inhibitors. Protein was eluted in the
presence of the above buffers under a flow rate of
8mlh-1. Four ml fractions were collected,
lyophilized and resuspended in 400p1 of distilled
water in order to estimate calcitonin. The column
was calibrated with blue dextran (Pharmacia,
Uppsala, Sweden), aldolase (Boehringer Mannheim,
FRG), bovine serum albumin, ovalbumin, chymo-
trypsinogen A (Pharmacia, Uppsala, Sweden),
myoglobin whale, cytochrome, c, cyanocobalamin,
bromophenol-blue (Serva, Heidelberg, FRG) and
[1251]-calcitonin (Immunonuclear, Stillwater, MN).
hCT-immunoreactive material was elevated
(> 100pgml-'1) in 20/101 (20%) patients with SCLC
compared to age and sex matched controls. In 54
(53%) of these patients elevated sCT-immuno-
reactive material (>1 ngml-1) was found (Figure
la). There was no correlation between the
calcitonins in patients sera. As shown in Figure lb,
elevated sCT immunoreactivity was seen in patients
with low as well as with high hCT immuno-
reactivity.
Concerning the stage of disease hCT-immuno-
reactive material was elevated in 18% of patients
with limited disease and in 34% of patients with
extensive disease. For sCT-like material the frequency
was 33% (limited disease) and 40% (extensive
disease) (Figure 2).
High amounts of the sCT-like material could be
detected in the incubation medium of several lung
cancer cell lines (Figure 3).
In the medium of the lung cancer cell lines the
sCT immunoreactivity was higher than the hCT-
immunoreactivity. In contrast, in the medium of the
medullary carcinoma cell lines hCT-immuno-
reactivity was higher than the sCT-immuno-
reactivity. The same trend was found in sera of 18
patients with medullary carcinoma. Here hCT was
elevated in 72%, whereas sCT was only elevated in
39%.
The chromatography results show the presence of
three immunoreactive forms of hCT with mol.w of
100,000, 48,000 and 20,000 daltons, all larger than
the physiological hCT. These results have been
described previously (Luster et al., 1982). The
simultaneous determination of sCT immuno-
reactivity detected four sCT immunoreactive
fractions with mol.w of 100,000, 25,000, 13,000 and
5,000 (Figure 4).
Our results show for the first time the coexistence
of elevated values of hCT- and sCT-like material in
the serum of patients with SCLC. It could be
demonstrated that both calcitonin immuno-
reactivities are secreted into the incubation medium
by cultured lung cancer cells.
Here, in contrast to studies with medullary
carcinoma cells, the values for sCT-like material are
higher than for the hCT-like material. The same
results were found in vivo where in lung cancer
patients the sCT values were higher than the hCT
values and in medullary cancer patients vice versa.
Our studies also confirm reports from Fischer et
al. (1983) who demonstrated both hCT and sCT in
human thyroid and brain. From our studies the
nature of the sCT-like material is not clear. From
recent investigations of the hCT in lung and
medullary cancer patients and from the chromato-
graphy studies it can be suggested that we detected
by radioimmunoassay an sCT precursor molecule
from which the sCT may derive. For hCT-like
material high molecular precursor forms with a
mol. w in the range from 8,000-55,000 daltons have
been isolated from lung and medullary carcinomas
(Luster et al., 1982, Jacobs et al., 1981; Desplan et
al., 1980; Roos et al., 1980; Allison et al., 1981). In
any case the sCT-like material may be of further
interest as a tumour marker in lung cancer patients.
Compared to other tumour markers, the incidence
of sCT-immunoreactive material was similar to
carcinoembryonic antigen (CEA) and neuron
specific enolase (NSE) in patients with SCLC. In
this tumour elevated CEA levels have been found in
-50% (Concannon et al., 1974, Vincent et al., 1973,
Gropp et al., 1978) and elevated NSE levels in 45-
69% (Gropp et al., unpublished, Carney et al., 1982).
Whereas elevated CEA and NSE values were
mostly observed in patients with extensive disease
there was no statistical difference for the frequency
of sCT-like material in patients with limited or
extensive SCLC. So sCT-determination probably
may be used in the future concomitantly with other
tumour markers in patients with SCLC. In
addition, further studies for the biochemical
characterization of the higher mol.wt sCT-fractions
are on the way.700 7 n = 101
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Figure la Salmon and human calcitonin serum values in patients with small cell lung cancer.
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Figure lb Salmon calcitonin serum values in patients with small cell lung cancer and low (i) and high (ii)
human calcitonin values.
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Figure 2 Salmon and human calcitonin values in patients with small cell lung cancer staged as limited and
extensive disease.
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Figure 3 Salmon (A) and human (0) calcitonin values, measured simultaneously in the culture medium of
different permanent lung cancer cell lines of various histology and in cell lines from medullary carcinomas of
the thyroid.
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Figure 4 AcA54 column chromatography of the culture medium of a small cell lung cancer cell line.
Fractions were assayed for salmon (A) and human (0) calcitonin.
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